Month: May 2022

Atlanta, GA, May 13, 2022 (GLOBE NEWSWIRE) — Trust Stamp (Nasdaq: IDAI, Euronext Growth: AIID ID), the Privacy-First Identity CompanyTM providing AI-powered trust and identity services used globally across multiple sectors, provides a business update and commentary on reported financial results for the three months ended March 31, 2022 (“Q1 2022”). First Quarter 2022 Financial Highlights:Net Revenue was $2.82M in Q1 2022 compared to $0.53M in Q1 2021, a 430.0% increase year-over-year Gross Profit was $2.13M in Q1 2022 compared to $0.27M in Q1 2021, a 673.8% increase year-over-year Gross Profit Margin for Q1 2022 was 75.4% compared to 51.6% for Q1 2021 Operating Loss decreased to $1.64M in Q1 2022 compared to $1.94M in Q1 2021 Net Profit Margin increased to -60.0% in Q1 2022 from -381.7% in Q1 2021 Net Loss was $1.69M in Q1 2022...

ORLANDO, Fla., May 13, 2022 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (Nasdaq: GENC) announced today net revenues of $30.7 million for the quarter ended March 31, 2022 compared to $21.4 million for the quarter ended March 31, 2021. Gross margins for the quarter ended March 31, 2022 were 20.2% compared with 28.8% for the quarter ended March 31, 2021. During the quarter ended March 31, 2022, the Company continued to experience higher manufacturing costs associated with wages, steel and OEM parts pricing. Product engineering and development expenses decreased $0.2 million to $0.9 million for the quarter ended March 31, 2022, as compared to $1.1 million for the quarter ended March 31, 2021, primarily related to reduced headcount. Selling, general and administrative (“SG&A”) expenses decreased by $0.5 million to $3.4 million for...

CHERRY HILL, N.J., May 13, 2022 (GLOBE NEWSWIRE) — The Real Good Food Company, Inc. (Nasdaq: RGF) (“Real Good Foods” or the “Company”), an innovative, high-growth, branded, health- and wellness-focused frozen food company, today reported financial results for its first quarter ended March 31, 2022. “We had strong momentum entering 2022 and I am pleased to report our first quarter results exceeded our expectations and we are raising our guidance for the full year,” said Bryan Freeman, Executive Chairman. “We achieved broad-based growth across our sales channels as well as significant sequential gross margin improvement in the first quarter. Due to productivity initiatives, we now expect to be Adjusted EBITDA positive in the fourth quarter of 2022. We believe we are still in the early stages of a robust long-term growth journey and...

Conference Call to Be Held Today at 10:00 am ET QUINCY, Mass., May 13, 2022 (GLOBE NEWSWIRE) — Stran & Company, Inc. (“Stran” or the “Company”) (NASDAQ: STRN) (NASDAQ: STRNW), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today provided a business update and reported financial results for the three months ended March 31, 2022. Andy Shape, President and CEO of Stran, commented, “We continue to successfully execute on our business strategy, as demonstrated by a 62.5% increase in revenue to $12.3 million for the first quarter of 2022, compared to the same period last year. Furthermore, we completed the highly synergistic and accretive acquisition of G.A.P. Promotions in January 2022. G.A.P. expands our reach within the beverage...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRES OR OTHER DISSEMINATION IN THE UNITED STATES TORONTO, May 13, 2022 (GLOBE NEWSWIRE) — Ceres Acquisition Corp. (NEO: CERE.U, CERE.WT; OTCQX: CERAF) (“Ceres” or the “Corporation”) is reporting its financial results as at March 31, 2022 and March 31, 2021, and for the three month periods then ended. The Corporation’s unaudited financial statements, along with the accompanying management’s discussion and analysis, have been filed on the System for Electronic Document Analysis and Retrieval (SEDAR) and may be viewed by interested parties under the Corporation’s profile at www.sedar.com. The Corporation is confident in its abilities to identify, evaluate and execute an attractive qualifying transaction by continuing to leverage its network to source a wide spectrum of meaningful investment opportunities. About...

All amounts in U.S. dollars unless otherwise stated TORONTO, May 13, 2022 (GLOBE NEWSWIRE) — Onex Corporation (TSX: ONEX) today announced its financial results for the first quarter ended March 31, 2022 and an update on matters following quarter-end. “Onex had a solid start to the year.  Our businesses continue to execute, and the fundamentals of our firm are strong.  Despite a challenging backdrop, our portfolio is performing well, reflecting the diversification and resiliency of our investments overall,” said Gerry Schwartz, Chairman and Chief Executive Officer of Onex. “We remain focused on delivering on our plan to grow our asset management business and increase long-term value for shareholders.” Financial Results(unaudited)($ millions except per share amounts) Three Months Ended March 31, 2022   Three Months Ended March...

Topline readout of Phase 2 AML trial Group 2 active disease anticipated in Q2 2022 Company plans to file INDs in lymphoma and pancreatic cancer by year end, with clinical trials to be initiated in 2023 HOUSTON, May 13, 2022 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022. “2022 has already been an exciting year for Marker as we reported encouraging initial results from the six-patient safety lead-in portion of our Phase 2 AML trial—including elimination of MRD in one MRD positive patient—and announced plans for Company-sponsored...

New data on lead oncology programs aumolertinib and sugemalimab to be presented at the 2022 ASCO Annual Meeting, including pre-specified interim overall survival (OS) data from the Phase 3 GEMSTONE-302 study of sugemalimab plus chemotherapy in first-line Stage IV NSCLC Continue to expect first regulatory submissions for aumolertinib and sugemalimab ex-U.S. in 2H 2022; constructive conversations with the FDA are ongoing to gain greater clarity on the regulatory path forward in the U.S. Continue to advance the Global Buyers Club; first conversion of a memorandum of understanding (MOU) to a pre-commercialization agreement EQRx to host conference call and webcast today at 8:00 a.m. ETCAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) — EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering...